MNKD (MannKind) Cyclically Adjusted Revenue per Share: $0.81 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MNKD MannKind Corp MNKD
66 GF Score
Price $4.19
GF Value $7.40
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is MannKind Cyclically Adjusted Revenue per Share?

MannKind MNKD -4.77% 66 Cyclically Adjusted Revenue per Share is $0.81 as of Jun. 2026. GuruFocus rates MNKD with a GF Score™ of 66/100 and a GF Value™ of $7.40 (Possible Value Trap). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

MannKind's adjusted revenue per share for the three months ended in Jun. 2026 was $0.354. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.81 for the trailing ten years ended in Jun. 2026.

During the past 12 months, MannKind's average Cyclically Adjusted Revenue Growth Rate was 11.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of MannKind was 7.00% per year. The lowest was -16.80% per year. And the median was 1.10% per year.

As of today (2026-08-20), MannKind's current stock price is $4.1852. MannKind's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $0.81. MannKind's Cyclically Adjusted PS Ratio of today is 5.17.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MannKind was 10.64. The lowest was 0.75. And the median was 5.22.


MannKind  (NAS:MNKD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

MannKind's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.1852/0.81
=5.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MannKind was 10.64. The lowest was 0.75. And the median was 5.22.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


MannKind Cyclically Adjusted Revenue per Share Related Terms


MannKind Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for MannKind's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MannKind Cyclically Adjusted Revenue per Share Chart

MannKind Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 0.62 0.65 0.70 0.76

MannKind Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 0.75 0.76 0.79 0.81

MNKD vs ABSI, ORIC, ARDX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, MannKind's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MannKind Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MannKind's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where MannKind's Cyclically Adjusted PS Ratio falls into.


MNKD
66GF Score
MannKind Corp MNKD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MannKind Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, MannKind's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.354/333.9520*333.9520
=0.354

Current CPI (Jun. 2026) = 333.9520.

MannKind Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.682 241.428 2.327
201612 0.130 241.432 0.180
201703 0.031 243.801 0.042
201706 0.022 244.955 0.030
201709 0.020 246.819 0.027
201712 0.039 246.524 0.053
201803 0.029 249.554 0.039
201806 0.028 251.989 0.037
201809 0.029 252.439 0.038
201812 0.099 251.233 0.132
201903 0.093 254.202 0.122
201906 0.080 256.143 0.104
201909 0.073 256.759 0.095
201912 0.077 256.974 0.100
202003 0.076 258.115 0.098
202006 0.071 257.797 0.092
202009 0.067 260.280 0.086
202012 0.079 260.474 0.101
202103 0.071 264.877 0.090
202106 0.093 271.696 0.114
202109 0.089 274.310 0.108
202112 0.050 278.802 0.060
202203 0.048 287.504 0.056
202206 0.074 296.311 0.083
202209 0.127 296.808 0.143
202212 0.137 296.797 0.154
202303 0.154 301.836 0.170
202306 0.183 305.109 0.200
202309 0.158 307.789 0.171
202312 0.217 306.746 0.236
202403 0.204 312.332 0.218
202406 0.265 314.175 0.282
202409 0.246 315.301 0.261
202412 0.264 315.605 0.279
202503 0.244 319.799 0.255
202506 0.246 322.561 0.255
202509 0.264 324.800 0.271
202512 0.354 324.054 0.365
202603 0.293 330.213 0.296
202606 0.354 333.952 0.354

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.81 mean?
MannKind (MNKD) has a Cyclically Adjusted Revenue per Share of $0.81 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MannKind and its competitors.
Is MannKind's Cyclically Adjusted Revenue per Share too high?
MannKind's current Cyclically Adjusted Revenue per Share is $0.81. Overall, MannKind has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MannKind's Cyclically Adjusted Revenue per Share compare to ABSI and ORIC?
MannKind's Cyclically Adjusted Revenue per Share of $0.81 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MannKind and its competitors. MannKind's current Cyclically Adjusted Revenue per Share is $0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MannKind stock overvalued right now?
Based on GuruFocus' analysis, MannKind (MNKD) is currently considered Possible Value Trap. The stock's GF Value™ is $7.40, compared to a current price of $4.19 — trading 43.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.81. MannKind's overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For MannKind (MNKD), the current Cyclically Adjusted Revenue per Share is $0.81 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MannKind (MNKD) Overvalued in 2026?

Based on GuruFocus' analysis, MannKind stock appears to be undervalued. The current stock price of $4.19 is trading 43.4% below its estimated GF Value™ of $7.40. GuruFocus considers MannKind to be Possible Value Trap.

Key valuation signals for MNKD:

  • Cyclically Adjusted Revenue per Share: $0.81
  • GF Value™: $7.40 vs. price of $4.19 (43.4% below fair value)
  • GF Score™: 66/100 with 8 warning signs

No single metric tells the full story. See the MNKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MannKind Business Description

Other Exchanges NNFN:Germany
Address 1 Casper Street, Danbury, CT, USA, 06810
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
66GF Score

Get the complete analysis for MNKD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.19
Price
$7.40
GF Value